Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 06, 2026
IEF vs TLT: Weighing Intermediate and Long-Duration Treasury ETFs

IEF vs TLT: Weighing Intermediate and Long-Duration Treasury ETFs

Key Takeaways

  • Both IEF and TLT are passive iShares ETFs tracking U.S. Treasury bond indices, offering pure exposure to government debt without credit risk.
  • IEF targets intermediate maturities (7-10 years) with approximately 16 holdings, effective duration around 6.85 years, and lower interest rate sensitivity.
  • TLT focuses on long-term maturities (20+ years) with approximately 47 holdings, effective duration around 14.63 years, resulting in higher volatility and greater sensitivity to rate changes.
  • Both funds maintain identical expense ratios of 0.15% and invest 100% in U.S. Treasuries, providing high liquidity and monthly distributions.
  • Structural differences center on duration and maturity profiles, making IEF suitable for moderate fixed-income exposure and TLT for investors seeking amplified duration in rate environments.
  • Both ETFs emphasize cost efficiency and transparency through index replication rather than active management or leverage.

Why These Two Treasury ETFs Matter

Investors looking for targeted exposure to the U.S. Treasury yield curve often find themselves comparing IEF and TLT. These ETFs do not compete directly but instead deliver complementary slices of the government bond market. IEF provides intermediate-duration exposure, while TLT emphasizes the long end of the curve. This distinction helps investors fine-tune interest rate risk and income characteristics within fixed-income allocations, especially as macroeconomic conditions shift around rate expectations and inflation trends. I also checked this using Tickeron’s AI Screener to see how the two line up against broader fixed-income peers.

A Closer Look at the iShares 7-10 Year Treasury Bond ETF (IEF)

The iShares 7-10 Year Treasury Bond ETF seeks to track the ICE U.S. Treasury 7-10 Year Bond Index. It holds approximately 16 U.S. Treasury securities with remaining maturities between seven and ten years. Top holdings typically include recently issued notes such as the Treasury Note (2OLD) and various 4.00%–4.63% notes maturing in 2034–2036. The fund maintains 100% allocation to Treasuries. Its expense ratio stands at 0.15%. As a passive index-tracking ETF, it employs full replication with periodic rebalancing to match the index. Key structural features include an effective duration of approximately 6.85 years and weighted average maturity of 8.45 years, positioning it for moderate interest rate sensitivity and stable income generation.

A Closer Look at the iShares 20+ Year Treasury Bond ETF (TLT)

The iShares 20+ Year Treasury Bond ETF seeks to track the ICE U.S. Treasury 20+ Year Bond Index. It holds approximately 47 U.S. Treasury securities with remaining maturities greater than twenty years. Top holdings consist of long-dated bonds such as the Treasury Bond 4.75% due 2055 and similar issues maturing in the 2050s. The fund maintains 100% allocation to Treasuries. Its expense ratio stands at 0.15%. As a passive index-tracking ETF, it employs full replication with periodic rebalancing. Key structural features include an effective duration of approximately 14.63 years and weighted average maturity of 26.08 years, resulting in elevated sensitivity to interest rate movements and higher potential for price volatility.

The Broader Treasury Market Context

The U.S. Treasury bond sector remains central to fixed-income strategies due to its role as a benchmark for risk-free rates and a haven asset. Macroeconomic drivers include Federal Reserve policy decisions on interest rates, inflation trajectories, and fiscal dynamics. Capital flows into intermediate and long-duration Treasuries often respond to expectations of rate cuts or economic slowdowns. Regulatory developments, such as changes in Treasury issuance patterns, and geopolitical events can influence supply and demand. Sector risks primarily involve interest rate fluctuations, with longer-duration instruments exhibiting amplified price movements. Both ETFs benefit from the high credit quality and liquidity of U.S. government debt amid broader fixed-income market rotations.

How IEF and TLT Have Positioned in Recent Cycles

In recent market cycles, IEF has demonstrated lower volatility compared with TLT due to its shorter duration profile. TLT experiences more pronounced price swings during shifts in interest rate expectations, reflecting its extended maturity exposure. Relative positioning favors IEF for investors prioritizing capital preservation within fixed income, while TLT aligns with strategies seeking greater responsiveness to rate declines. Performance differentials arise from duration-driven sensitivity rather than credit or sector allocation variances, as both funds remain fully invested in Treasuries. Liquidity profiles support efficient trading for both, though TLT typically records higher average daily volumes. From what I see, the choice often comes down to how much rate sensitivity an investor wants to carry.

Using Tickeron’s AI Screener in My Research

In my own workflow, I turn to Tickeron’s AI Screener when comparing fixed-income ETFs like these. The tool lets me filter across technical patterns, fundamentals, volatility metrics, and AI-driven signals to quickly surface ideas that align with a specific duration or risk profile. It has helped me identify how IEF and TLT stack up against other Treasury vehicles without manually sorting through dozens of screens. I find it especially useful for spotting relative strength or breakout candidates within the sector.

AI-Assisted Perspective on the Two Funds

Based on structural characteristics, Tickeron’s AI would currently assign a modestly higher probability of favorability to IEF. Its lower duration reduces exposure to interest rate volatility while maintaining competitive cost efficiency and adequate diversification within the intermediate Treasury segment. TLT offers compelling duration for specific rate-view strategies but carries elevated risk. This assessment draws from observable factors including duration profile, holdings concentration, and sector momentum rather than short-term price action. I’m watching this closely as rate paths evolve.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IEF, TLT

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


IEF's Indicator enters downward trend

The Aroon Indicator for IEF entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 239 similar instances where the Aroon Indicator formed such a pattern. In 152 of the 239 cases the stock moved lower. This puts the odds of a downward move at 64%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IEF turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 20 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IEF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where IEF advanced for three days, in 165 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

IEF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Industry description

The investment seeks to track the investment results of the ICE® U.S. Treasury 7-10 Year Bond Index. The underlying index consists of publicly-issued U.S. Treasury securities that have a remaining maturity of greater than or equal to seven years and less than ten years and have $300 million or more of outstanding face value, excluding amounts held by the Federal Reserve System (the “Fed”). The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in U.S. Treasury securities that BFA believes will help the fund track the underlying index.
View a ticker or compare two or three
IEF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category LongGovernment

Category
Long Government
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.